(Albany, United States) As per DelveInsight’s assessment, globally, the Acute Myeloid Leukemia pipeline constitutes 260+ key companies continuously working towards developing 260+ Acute Myeloid Leukemia treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analysis DelveInsight.

 

In the Acute Myeloid Leukemia pipeline report, detailed description of the drug is given which includes mechanism of action of the drug, Acute Myeloid Leukemia clinical trials, NDA approvals (if any), and product development activities comprising the technology, Acute Myeloid Leukaemia collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

 

To explore more information on the latest breakthroughs in the Acute Myeloid Leukemia pipeline treatment landscape of the report, click here @ Acute Myeloid Leukemia Pipeline Outlook

 

Key Takeaways from the Acute Myeloid Leukemia Pipeline Report

• DelveInsight’s Acute Myeloid Leukemia Pipeline analysis depicts a robust space with 260+ active players working to develop 260+ pipeline treatment therapies.
• The leading Acute Myeloid Leukemia Companies working in the market include GlycoMimetics, CSPC ZhongQi Pharmaceutical Technology Co., Ltd., Takeda Oncology, Orca Bio, Gilead Sciences, Actinium Pharmaceuticals, Kronos Bio, Bristol-Myers Squibb, ImmunityBio, Bellicum Pharmaceuticals, TC BioPharm, Syros Pharmaceuticals, Armaceutica, Teva Pharmaceutical Industries, New Epsilon Innovation Limited, MediGene, TC Biopharm, PersonGen BioTherapeutics, Oncoceutics, Janssen Research & Development, LLC, Immune-Onc Therapeutics, Novartis, Jasper Therapeutics, Agastiya Biotech, Poseida Therapeutics, Molecular Partners, Allogene Therapeutics, and others
• Promising Acute Myeloid Leukemia Pipeline Therapies in the various stages of development include OCV-501, SEL24/MEN1703, Venetoclax, Alvocidib, TL-895, KRT-232, XY0206, and others
• On July 2023, AbbVie announced a study of phase 3 clinical trials for Azacitidine and Venetoclax. In this study, 2/3 of participants will receive venetoclax every day with azacitidine and the remaining 1/3 will receive placebo (dummy) tablets with azacitidine.
• On May 2023, Menarini Group announced a study of phase 1 & 2 clinical trials for SEL24/MEN1703. The purpose of the clinical trial is to identify the maximum tolerated dose of SEL24/MEN1703 and to further investigate its safety profile in patients with Acute Myeloid Leukemia.
• On February 2023, Telios Pharma Inc announced a study of phase 1 & 2 clinical trials for TL-895 and KRT-232. This study evaluates TL-895, a potent, orally available and highly selective irreversible tyrosine kinase inhibitor combined with navtemadlin (KRT-232), a novel oral small molecule inhibitor of MDM2 for the treatment of adults with FLT3 mutated Acute Myeloid Leukemia. Participants must be relapsed/refractory (e.g., having failed prior therapy) to be eligible for this study.

 

Acute Myeloid Leukemia Overview

Acute myeloid leukemia (AML) is the most common leukemia among the adult population and accounts for about 80% of all cases. It is characterized by clonal expansion of immature “blast cells” in the peripheral blood and bone marrow resulting in ineffective erythropoiesis and bone marrow failure.

 

To explore more information on the latest breakthroughs in the Acute Myeloid Leukemia Pipeline treatment landscape of the report, click here @ https://www.delveinsight.com/sample-request/acute-myeloid-leukemia-aml-pipeline-insight

 

Acute Myeloid Leukemia Emerging Drugs Profile

• Omidubicel: Gamida Cell
• Uproleselan: GlycoMimetics
• ALT 803: ImmunityBio
• BPX-501: Bellicum Pharmaceuticals

 

Acute Myeloid Leukemia Pipeline Therapeutics Assessment

There are approx. 260+ key companies which are developing the Acute Myeloid Leukaemia therapies. The Acute Myeloid Leukaemia companies which have their Acute Myeloid Leukaemia drug candidates in the most advanced stage, i.e preregistration include Gamida Cell.

 

Request a sample and discover the recent advances in Acute Myeloid Leukemia Ongoing Clinical Trial Analysis and Medications, click here @ https://www.delveinsight.com/sample-request/acute-myeloid-leukemia-aml-pipeline-insight

 

Acute Myeloid Leukemia Drugs and Companies

• OCV-501: Otsuka Pharmaceuticals Co Ltd
• SEL24/MEN1703: Menarini Group
• Venetoclax: AbbVie
• Alvocidib: Sumitomo Pharma Oncology Inc
• TL-895: Telios Pharma Inc
• KRT-232: Kartos Therapeutics Inc

 

Acute Myeloid Leukemia Therapeutics Assessment

• Assessment by Stage and Product Type
• Assessment by Route of Administration
• Assessment by Stage and Route of Administration
• Assessment by Molecule Type
• Assessment by Stage and Molecule Type

 

Some of the Companies in the Acute Myeloid Leukemia Therapeutics Market include-

GlycoMimetics, CSPC ZhongQi Pharmaceutical Technology Co., Ltd., Takeda Oncology, Orca Bio, Gilead Sciences, Actinium Pharmaceuticals, Kronos Bio, Bristol-Myers Squibb, ImmunityBio, Bellicum Pharmaceuticals, TC BioPharm, Syros Pharmaceuticals, Armaceutica, Teva Pharmaceutical Industries, New Epsilon Innovation Limited, MediGene, TC Biopharm, PersonGen BioTherapeutics, Oncoceutics, Janssen Research & Development, LLC, Immune-Onc Therapeutics, Novartis, Jasper Therapeutics, Agastiya Biotech, Poseida Therapeutics, Molecular Partners, Allogene Therapeutics, and others.

 

Dive deep into rich insights for drugs for Acute Myeloid Leukemia Pipeline, click here for Acute Myeloid Leukemia Unmet Needs and Analyst Views @ https://www.delveinsight.com/sample-request/acute-myeloid-leukemia-aml-pipeline-insight

 

Scope of the Acute Myeloid Leukemia Pipeline Report

• Coverage- Global
• Acute Myeloid Leukemia Companies- GlycoMimetics, CSPC ZhongQi Pharmaceutical Technology Co., Ltd., Takeda Oncology, Orca Bio, Gilead Sciences, Actinium Pharmaceuticals, Kronos Bio, Bristol-Myers Squibb, ImmunityBio, Bellicum Pharmaceuticals, TC BioPharm, Syros Pharmaceuticals, Armaceutica, Teva Pharmaceutical Industries, New Epsilon Innovation Limited, MediGene, TC Biopharm, PersonGen BioTherapeutics, Oncoceutics, Janssen Research & Development, LLC, Immune-Onc Therapeutics, Novartis, Jasper Therapeutics, Agastiya Biotech, Poseida Therapeutics, Molecular Partners, Allogene Therapeutics, and others.
• Acute Myeloid Leukemia Pipeline Therapies- OCV-501, SEL24/MEN1703, Venetoclax, Alvocidib, TL-895, KRT-232, XY0206, and others.
• Acute Myeloid Leukemia Segmentation: Product Type, Molecule Type, Route of Administration

 

Got Queries? Find out the related information on Acute Myeloid Leukemia Mergers and acquisitions, Licensing Activities @ https://www.delveinsight.com/sample-request/acute-myeloid-leukemia-aml-pipeline-insight

 

Table of Content

1. Introduction
2. Executive Summary
3. Acute Myeloid Leukaemia: Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. Acute Myeloid Leukaemia– DelveInsight’s Analytical Perspective
7. Late Stage Products (Preregistration)
8. Omidubicel: Gamida Cell
9. Drug profiles in the detailed report…..
10. Mid Stage Products (Phase III)
11. Uproleselan: GlycoMimetics
12. Drug profiles in the detailed report…..
13. Mid Stage Products (Phase II)
14. ALT 803: ImmunityBio
15. Early Stage Products (Phase I)
16. JNJ-75276617: Janssen Research & Development, LLC
17. Drug profiles in the detailed report…..
18. Preclinical Stage Products
19. AB001: Agastiya Biotech
20. Drug profiles in the detailed report…..
21. Inactive Products
22. Acute Myeloid Leukaemia Key Companies
23. Acute Myeloid Leukaemia Key Products
24. Acute Myeloid Leukaemia- Unmet Needs
25. Acute Myeloid Leukaemia- Market Drivers and Barriers
26. Acute Myeloid Leukaemia- Future Perspectives and Conclusion
27. Acute Myeloid Leukaemia Analyst Views
28. Acute Myeloid Leukaemia Key Companies
29. Appendix

 

About Us

DelveInsight is a Business Consulting and Market research company, providing expert business solutions for the healthcare domain and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers & Acquisitions.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/consulting-services